Group items tagged

CONCLUSIONS: Supplementation with n-3 PUFA improves biochemical, ultrasonographic and haemodynamic features of liver steatosis. Our study supports the efficacy of n-3 PUFA as a new therapeutic approach in the treatment of NAFLD. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1143-51. PMID: 16611275 DOI: 10.1111/j.1365-2036.2006.02885.x

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R. J Hepatol. 2007 Nov;47(5):711-7. Epub 2007 Aug 14. PMID: 17850914 doi:10.1016/j.jhep.2007.06.020    

A lipidomic analysis of nonalcoholic fatty liver disease. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. Hepatology. 2007 Oct;46(4):1081-90. PMID: 17654743 DOI: 10.1002/hep.21763